• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Aptevo Therapeutics

    Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia
    From Aptevo Therapeutics
    Via AccessWire
    Tickers APVO
    Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
    From Aptevo Therapeutics
    Via AccessWire
    Tickers APVO
    APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting
    From Aptevo Therapeutics
    Via AccessWire
    Tickers APVO
    Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia
    From Aptevo Therapeutics
    Via AccessWire
    Tickers APVO
    Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update
    From Aptevo Therapeutics
    Via AccessWire
    Tickers APVO
    Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update
    From Aptevo Therapeutics
    Via AccessWire
    Tickers APVO
    Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022
    From Aptevo Therapeutics
    Via AccessWire
    Topics Retirement
    Exposures Pension
    Tickers APVO
    Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"
    From Aptevo Therapeutics
    Via AccessWire
    Tickers APVO
    Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia
    From Aptevo Therapeutics
    Via AccessWire
    Exposures COVID-19
    Tickers APVO
    Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting
    From Aptevo Therapeutics
    Via AccessWire
    Exposures COVID-19
    Tickers APVO
    Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights
    From Aptevo Therapeutics
    Via AccessWire
    Exposures COVID-19
    Tickers APVO
    Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021
    From Aptevo Therapeutics
    Via AccessWire
    Exposures COVID-19
    Tickers APVO
    Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting
    From Aptevo Therapeutics
    Via AccessWire
    Exposures COVID-19
    Tickers APVO
    Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021
    From Aptevo Therapeutics
    Via AccessWire
    Exposures COVID-19
    Tickers APVO
    Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436
    From Aptevo Therapeutics
    Via AccessWire
    Exposures COVID-19
    Tickers APVO
    Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging
    From Aptevo Therapeutics
    Via AccessWire
    Exposures COVID-19
    Tickers APVO
    Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
    From Aptevo Therapeutics
    Via AccessWire
    Exposures COVID-19
    Tickers APVO
    Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
    From Aptevo Therapeutics
    Via AccessWire
    Exposures COVID-19
    Tickers APVO
    Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference
    From Aptevo Therapeutics
    Via AccessWire
    Exposures COVID-19
    Tickers APVO
    Aptevo Therapeutics' Scientists to Present At Virtual Cell Engager Summit
    From Aptevo Therapeutics
    Via AccessWire
    Exposures COVID-19
    Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
    From Aptevo Therapeutics
    Via AccessWire
    Exposures COVID-19 Lead
    Tickers APVO
    Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia
    From Aptevo Therapeutics
    Via AccessWire
    Exposures COVID-19
    Tickers APVO
    Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia
    From Aptevo Therapeutics
    Via AccessWire
    Topics Death Intellectual Property
    Exposures COVID-19 Death Intellectual Property
    Tickers APVO
    Aptevo Therapeutics Reports First Quarter 2021 Financial Results
    From Aptevo Therapeutics
    Via AccessWire
    Exposures COVID-19
    Tickers APVO
    Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
    From Aptevo Therapeutics
    Via AccessWire
    Exposures COVID-19
    Tickers APVO
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.